Drug intelligence / Profile preview

CTL-DISC01

Development stage: Preclinical
Lead developer: CatalYm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CTL-DISC01 is a discovery-stage therapeutic program being developed by CatalYm, focusing on the inhibition of Growth Differentiation Factor 15 (GDF-15) for the treatment of cancer. GDF-15 is a stress-induced cytokine that is frequently overexpressed in solid tumors and acts as a key mediator of immune escape by excluding T-cells from the tumor microenvironment. By targeting GDF-15, CTL-DISC01 aims to reverse this immunosuppression and enhance the effectiveness of anti-tumor immune responses, potentially working in synergy with checkpoint inhibitors. The program leverages CatalYm's expertise in GDF-15 biology and its platform for developing neutralizing antibodies to overcome resistance to current immuno-oncology treatments.

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on CTL-DISC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTL-DISC01.

Explore the full profile